[Human papillomavirus disease burden in men : HPV prevention is a man's business]

[Human papillomavirus (HPV) vaccination for cancer prevention]

BACKGROUND

In 2005, the first approval study of a preventive quadrivalent human papillomavirus (HPV) vaccine in young women triggered vaccination strategies around the world.

OBJECTIVE

We aimed to investigate how successful these vaccination interventions have been in preventing cancer so far.

METHODS

To this end, we reviewed the relevant literature of the past two decades regarding vaccination rates and the subsequent decline in HPV-associated diseases worldwide.

RESULTS

For various reasons, many countries that offer HPV vaccinations are still missing their goals for primary cancer prevention. In Germany, for example, vaccination rates are completely inadequate, and urologists are not even recognized as vaccinators.

CONCLUSION

Cancer prevention through HPV vaccination is zur Hausen's scientific legacy to the world. However, each country must continuously analyze and combat its specific reasons for failing in HPV vaccination. New HPV vaccines will continue the global success story in the future.

Human papillomavirus prevalence and genotype distribution in Liaocheng men between 2016 and 2022

Human papillomavirus (HPV) infection can lead to HPV-related cancer in men, including the anus, penile, and oropharyngeal cancers and precancerous lesions. This study retrospectively investigated HPV prevalence and genotype distribution in Liaocheng men between 2016 and 2022. The total HPV positive rate was 64.87% (2388/3681, 95% confidence interval [CI]: 63.32%-66.40%), where high risk (HR)-HPV and low risk (LR)-HPV accounted for 42.49% (1564/3681, 95% CI: 40.90%-44.09%) and 69.71% (2566/3681, 95% CI: 68.20%-71.17%), respectively. The mixed HPV infection rate of two and more genotypes was 35.72%. The infection rate of HR-HPV increased with the number of positive cases annually from 2016 (16.91%) to 2022 (46.59%). The most common HR-HPV genotypes were HPV16 (11.60%), HPV52 (6.95%), and HPV59 (6.28%), whereas the least common HR-HPV was HPV26. The most common LR-HPV genotypes were HPV6 (56.99%), HPV11 (23.79%), and HPV43 (6.37%). The 9 v HPV vaccine preventable for LR-HPV and HR-HPV accounted for 80.78% and 30.40%, respectively, in this study. Most HPV-positive patients aged 1-86 were in the 30-39 age group. This study confirmed that HPV prevalence in Liaocheng men was common and diverse. HPV16, HPV52, and HPV59 are widely distributed in Liaocheng men, and the male HR-HPV infection rate remained high in this region. Regarding public health and cancer prevention, it is recommended and effective to include the HPV vaccination in the national vaccination program for men.

Prevention Strategies and Early Diagnosis of Cervical Cancer: Current State and Prospects

Cervical cancer ranks third among all new cancer cases and causes of cancer deaths in females. The paper provides an overview of cervical cancer prevention strategies employed in different regions, with incidence and mortality rates ranging from high to low. It assesses the effectiveness of approaches proposed by national healthcare systems by analysing data published in the National Library of Medicine (Pubmed) since 2018 featuring the following keywords: "cervical cancer prevention", "cervical cancer screening", "barriers to cervical cancer prevention", "premalignant cervical lesions" and "current strategies". WHO's 90-70-90 global strategy for cervical cancer prevention and early screening has proven effective in different countries in both mathematical models and clinical practice. The data analysis carried out within this study identified promising approaches to cervical cancer screening and prevention, which can further enhance the effectiveness of the existing WHO strategy and national healthcare systems. One such approach is the application of AI technologies for detecting precancerous cervical lesions and choosing treatment strategies. As such studies show, the use of AI can not only increase detection accuracy but also ease the burden on primary care.

[The urologist as a vaccinator]

Impfmedizin zählt zu den effektivsten Waffen der Menschheit im Kampf gegen unterschiedliche Infektionskrankheiten. Ärzte aller Fachrichtungen sollten deshalb nicht nur regelmäßig Kenntnis von Impfungen erlangen, sondern diese auch aktiv in ihrer täglichen Arbeit anbieten. Urologen können gleich mit diversen Impfangeboten dazu beitragen, die Gesundheit ihrer Patienten zukünftig besser zu schützen. Neben HPV-Impfung (humane Papillomaviren) von Kindern und Jugendlichen soll gerade auch an Patienten über 60 Jahren in diesem Beitrag gezeigt werden, wie Urologen als Impfärzte ihrer Verantwortung zur Umsetzung der staatlichen Impfempfehlungen nachkommen können. Unter anderem können HPV-Impfungen bewirken, eine evolutionäre Erblast der Menschheit endlich zu tilgen. Spezielle Altersimpfungen ab 60 Jahren sollen neben Standardimpfungen gegen Tetanus, Diphtherie und Pertussis insbesondere auch vor Pneumokokken, Influenza und Herpes zoster schützen. Und eines Tages werden Urologen möglicherweise Patienten auch vor COVID-19 („coronavirus disease 2019“) bewahren, die Krankheit, die Impfungen aktuell wieder ins globale Bewusstsein rückte.

[Improvement of vaccination activities in urology]

Effective vaccines against various urologically important diseases have been established for a long time, nevertheless, vaccination activities are generally underperformed in urology. Consistently low vaccination rates, e.g. for human papillomavirus (HPV) vaccines and a widespread vaccination hesitancy characterize the situation especially in men. This article highlights the importance of various aspects of vaccinations in urology and focuses on the improvement of consultation techniques for vaccinations to increase the vaccination rate and acceptance in the future.